ProFibrix Raises US $11 Million (EUR 8 million) in Series B Financing

    LEIDEN, The Netherlands and SEATTLE, Aug. 24 /CNW/ - ProFibrix B.V., a
leader in the development of innovative products for hemostasis and
regenerative medicine, today announced the successful closing of a US $11
million series B investment. The financing round was led by new investor Gilde
Healthcare Partners, a leading European life sciences investor, who joins
existing investor Index Ventures. Dirk Kersten from Gilde will join the
company's Supervisory Board.
    Jaap Koopman, PhD, Chief Executive Officer, said: "We are very pleased to
welcome Gilde Healthcare to our investor base and we appreciate the ongoing
support and expertise that our investors can offer to our experienced team as
we continue the development of ProFibrix. The proceeds of the financing will
be applied to the ongoing clinical development of our lead product
Fibrocaps(TM), and to the preclinical development of our pipeline products."
    Fibrocaps is based on a mixture of two essential blood clotting proteins,
fibrinogen and thrombin, and is a unique dry powder topical tissue sealant
that rapidly stops bleeding after or during surgery. Fibrocaps has major
advantages over existing liquid tissue sealants: it is ready for immediate
use, is stable at room temperature, highly effective and fast acting.
Fibrocaps is currently in a Phase II clinical trial in the Netherlands with
results expected end of 2009.
    Dirk Kersten, investment manager at Gilde Healthcare Partners, commented:
"Gilde Healthcare Partners invests in biopharmaceutical companies with strong
technology platforms and experienced management. We believe ProFibrix'
breakthrough fibrinogen technology is well-positioned to play an important
role in the highly attractive hemostasis and regenerative medicine markets."
    ProFibrix expects to submit an Investigational New Drug Application (IND)
for Fibrocaps to the U.S. Food and Drug Administration in the first half of
2010, and to conduct a combined phase II/III pivotal study in various surgical

    About ProFibrix

    ProFibrix ( was founded in 2004 and is
headquartered in Leiden, The Netherlands, with a subsidiary in Seattle, WA,
USA The company leverages its expertise in fibrinogen technology to develop
and market innovative products for the hemostasis and regenerative medicine
markets. Human fibrinogen plays a pivotal role in blood clotting and tissue
healing. ProFibrix is led by a team with extensive commercial, clinical and
scientific experience in the hemostasis field.

    About Gilde Healthcare Partners

    Gilde Healthcare Partners ( founded in 2000
is headquartered in Utrecht, the Netherlands with representatives in London
and Madrid. Gilde Healthcare Partners has over EUR 275 million under
management and is actively looking to lead new investments in therapeutics,
diagnostics, medical devices and enabling technologies. Gilde is a successful
builder of healthcare businesses across Europe. By investing in companies with
clear achievable business models, Gilde has used its financial resources and
network to create significant value for both its investors and the
entrepreneurs it backs. Companies that Gilde Healthcare Partners has
proactively supported span all aspects of healthcare and include Ablynx
(Belgium), Acacia Pharma (UK), Agendia (Netherlands), AMT (Netherlands),
Ascendis Pharma (Denmark), Chroma Therapeutics (UK), Conatus (US), Flowcardia
(US), Glycart (Switzerland), Santaris Pharma (Denmark) and Symphogen
(Denmark). For a full list of Gilde's portfolio companies please visit

    About Index Ventures

    Index Ventures is a leading pan-European venture capital firm dedicated
to working with entrepreneurs who have the drive and ability to build
world-class technology and life science companies. The Index Ventures team,
which began investing in 1992, has a deep technology and scientific focus and
the ability to leverage a network of cross-Atlantic strategic relationships.
Index proactively seeks out the top entrepreneurial teams in each investment
area and leverages its core assets in helping the entrepreneurs build their
companies into global leaders. Index Ventures investors include leading
technology firms and institutional investors. Previous investments include
Addex Pharmaceuticals, Genmab, SGX Pharmaceuticals, Inc., Ingenium, ParAllele
Bioscience, Molecular Partners and PanGenetics. Further information on Index
Ventures can be found at

For further information:

For further information: ProFibrix B.V., Jaap Koopman, Ph.D., CEO, Tel:
+ 31(0)6-21628475, E-mail:; ProFibrix Inc., Jan
Ohrstrom MD, COO, Tel: + 1-2069105404, E-mail:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890